Prevalence and Correlates of Symptoms of Cannabinoid Hyperemesis Syndrome in the United States
| Journal | medRxiv : the preprint server for health sciences |
| Study Type | Cohort |
| Population | Human participants |
This is the first nationally representative study to quantify CHS prevalence outside clinical settings, revealing that nearly 1 in 5 daily cannabis users experience severe gastrointestinal symptoms. For clinicians, this transforms CHS from a rare case report phenomenon to a predictable complication affecting millions of Americans.
This cross-sectional survey of 7,034 US adults found that 15.2% reported daily cannabis use in the past 5 years, representing over 40 million Americans. Among daily users, 17.8% reported CHS-like symptoms including severe nausea, vomiting, or abdominal pain. The study provides the first population-level prevalence data for CHS symptoms, moving beyond case series and emergency department reports. Key limitation is the reliance on self-reported symptoms rather than clinical diagnosis, though this may actually capture the true burden including undiagnosed cases.
“I’ve been seeing more CHS cases in practice, but this data suggests the scope is far larger than most clinicians realize. This prevalence rate means every physician should be routinely screening heavy cannabis users for gastrointestinal symptoms.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
How common is Cannabinoid Hyperemesis Syndrome among daily cannabis users?
According to this national survey, 17.8% of daily cannabis users reported CHS-like symptoms including severe nausea, vomiting, or abdominal pain. This represents a significant portion of the estimated 40+ million US adults who use cannabis daily, suggesting CHS is more prevalent than previously recognized in clinical settings.
What patient population should clinicians screen for CHS?
Clinicians should particularly consider CHS screening in patients with a history of daily cannabis use over multiple years who present with unexplained severe nausea, vomiting, or abdominal pain. The condition appears to be associated with heavy, chronic cannabis use patterns rather than occasional use.
How should I counsel patients about CHS risk with daily cannabis use?
Patients should be informed that daily cannabis use carries a nearly 1 in 5 risk of developing CHS-like symptoms. Counseling should emphasize that CHS is an emerging condition characterized by persistent, severe gastrointestinal symptoms that may require cessation of cannabis use for resolution.
What are the key diagnostic features of CHS I should look for?
CHS is characterized by persistent and severe nausea and vomiting in patients with heavy cannabis use history. The syndrome may also include severe abdominal pain, and symptoms typically improve with cannabis cessation, distinguishing it from other causes of cyclic vomiting.
How significant is CHS as a public health concern?
With over 40 million US adults using cannabis daily and nearly 18% experiencing CHS-like symptoms, this represents a substantial public health issue affecting millions of Americans. The high prevalence suggests clinicians will increasingly encounter this condition as cannabis use continues to rise nationally.
